- |||||||||| budesonide / Generic Mfg.
Clinical, Journal: Analysis of the advantages and disadvantages in application of oxygen-driven aerosol and aerosol inhalation by air compressor for the pediatric asthma. (Pubmed Central) - Sep 6, 2019
...Patients in both groups received 0.5 mg budesonide suspension, 0.2 mg salbutamol and 4 mL normal saline, and following the treatment, we recorded the excellence rate, improvement rate, total effectiveness rate, and the changes in oxyhemoglobin saturation (SaO2) before and after treatment, and the remission time in two groups...Both of the oxygen-driven aerosol inhalation and aerosol inhalation by air compressor can improve the clinical symptoms of pediatric asthma effectively, but oxygen-driven aerosol inhalation works more efficiently, with an elevated SaO2. Thus, oxygen-driven aerosol inhalation is preferred in clinical practice.
- |||||||||| budesonide / Generic Mfg.
Journal: Top POEMs of 2018 Consistent with the Principles of the Choosing Wisely Campaign. (Pubmed Central) - Sep 4, 2019
These POEMs describe interventions whose benefits are not superior to other options, are sometimes more expensive, or put patients at increased risk of harm. Knowing more about these POEMs and their connection with the Choosing Wisely campaign will help clinicians and their patients engage in conversations better informed by high-quality evidence.
- |||||||||| budesonide / Generic Mfg.
Journal: The inhibition of 18β-sodium glycyrrhetinic acid on thymic stromal lymphopoietin expression in the nasal mucosa of allergic rhinitis rats (Pubmed Central) - Sep 3, 2019
One hundred Wistar rats,half male and half female,were randomly divided into 5 groups by random number table control group, AR model group,budesonide group,18β-sodium glycyrrhetinic acid at dose of 20 mg/kg and 40 mg/kg groups, with 20 rats in each group...With the inhibition of TSLP, the concentrations of IL-4 and OVA-sIgE in rat serum were also decreased. 18β-sodium glycyrrhetinic acid has obvious inhibitory effect on TSLP in nasal mucosa of AR rats, which can control Th2 type immune inflammatory reaction.
- |||||||||| budesonide / Generic Mfg.
Journal: Intestinal permeability determinants of norfloxacin in Ussing chamber model. (Pubmed Central) - Aug 30, 2019
Furthermore, this work revealed that NFX has itself an affinity for OCTN and OATP, demonstrating that NFX could inhibit these transporters and influence the absorption of other drugs. The updated description of NFX intestinal permeability factors could contribute to the development of rational pharmaceutical formulations that could circumvent the efflux problems and consequently improve NFX biopharmaceutical properties and avoid drug-drug interactions.
- |||||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Preclinical, Journal: Ranking in vitro dissolution of inhaled micronized drug powders including a candidate drug with two different particle sizes. (Pubmed Central) - Aug 30, 2019
Furthermore, a relation between in vitro dissolution rate (t63) and mean pulmonary absorption time in man (literature data) was observed, indicating clinical relevance. It is thus concluded that the method may be useful for the characterization and ranking of drug substances and drug products in early development, as well as being a potential tool for the control of dissolution as a potential quality attribute.
- |||||||||| budesonide / Generic Mfg.
Journal: Multi-Solvent Microdroplet Evaporation: Modeling and Measurement of Spray-Drying Kinetics with Inhalable Pharmaceutics. (Pubmed Central) - Aug 28, 2019
It is thus concluded that the method may be useful for the characterization and ranking of drug substances and drug products in early development, as well as being a potential tool for the control of dissolution as a potential quality attribute. Numerical and experimental analysis of multi-solvent systems indicate that spray-drying near the iso-compositional ratio simplifies the design and process development of such systems.
- |||||||||| budesonide / Generic Mfg.
Review, Journal: IgA nephropathy: un update. (Pubmed Central) - Aug 27, 2019
Complement activation contributes to the pathogenic process of IgAN with evidence from genetic, serological, histological and in vitro studies[5]. This knowledge has translated to clinical trials of investigational agents directly targeting the alternative pathway.
- |||||||||| budesonide / Generic Mfg.
Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma (6F) - Aug 26, 2019 - Abstract #ERS2019ERS_6031;
The total severe and non-severe exacerbation rate was also lower in the as-needed budesonide-formoterol group (0.165 vs 0.237; relative rate, 0.70 [95% CI 0.51 to 0.95]; p=0.024). Conclusion In adults with mild asthma, budesonide-formoterol used as required for relief of symptoms is more effective at preventing severe exacerbations than maintenance low dose budesonide plus as-needed terbutaline.
- |||||||||| budesonide / Generic Mfg.
Late Breaking Abstract - Impact of COPD symptom-related attacks on quality of life and exacerbations (6F) - Aug 26, 2019 - Abstract #ERS2019ERS_5775;
Previous post-hoc analysis of the RISE study showed that mild exacerbations, or COPD symptom-related attacks, were common and reduced by budesonide/formoterol pMDI 320/9µg vs. formoterol DPI 9µg (Ferguson et al... COPD symptom-related attacks are not “mild” but signify clinically morbid events associated with a decline in HRQoL and an increased risk of moderate/severe exacerbations.
- |||||||||| budesonide / Generic Mfg.
ICS/LABA effects on antiviral innate immune response. An in vitro analysis. (N104) - Aug 26, 2019 - Abstract #ERS2019ERS_5229;
Here, we evaluated by qRT-PCR the modulatory effect of the ICS Budesonide (Bud), alone or in combination with the LABA Formoterol (Form), on interferon stimulated gene (ISG) expression and viral genome quantification in bronchial epithelial cells...Furthermore, we observed an increase of viral RNA after exposure to 10nM Bud (1.5-fold) but not Form. Thus, Bud and to a lesser extent Form impaired the early innate immune response in bronchial epithelial cells by suppression of antiviral ISG expression, an effect potentiated by the combination Bud/Form.
- |||||||||| budesonide / Generic Mfg.
Budesoinde/formoterol: does eosinophil count cause different outcomes? (TP-17) - Aug 26, 2019 - Abstract #ERS2019ERS_4473;
Treatment with budesonide/formoterol (Easyhaler) cause statistically significant change in ACQ-6, FEV1 and PEF for both EA and NEA, but the number of patients with UA and PCA was higher in patients with EA. No statistically significant change in number of exacerbations was found for EA.
- |||||||||| budesonide / Generic Mfg.
Side effects of inhaled budesonide through different types of inhalers (TP-16) - Aug 26, 2019 - Abstract #ERS2019ERS_4453;
Among patients with signs of dysphonia, the highest rate was in the group using pMDI - 42.5%, and a significantly lower rate was in patients using easyhaler - 27.3%. In patients with signs of oral candidiasis, the highest rate was also in 1st group and was 7.5%, while in 2nd group it was slighty lower - 4.5%.
- |||||||||| budesonide / Generic Mfg.
Discrete choice experiments identifying attributes influencing treatment preference in mild asthma (TP-14) - Aug 26, 2019 - Abstract #ERS2019ERS_4415;
Aim To determine the relative importance to participants in the PRACTICAL study, a 12-month open-label RCT of symptom-driven budesonide-formoterol versus regular budesonide plus as-needed terbutaline, of attributes distinguishing these regimens...Conclusions In these DCEs, participant’s preferences were influenced by several attributes in addition to as-needed versus regular treatment. The relative importance of such attributes should be considered during shared decision-making with patients.
- |||||||||| budesonide / Generic Mfg.
What do patients want? Preferences for two asthma regimens in mild/moderate asthma (TP-14) - Aug 26, 2019 - Abstract #ERS2019ERS_4414;
Introduction In the SYGMA trials in mild asthma, as needed budesonide-formoterol (BUD/FORM) was non-inferior to regular low-dose budesonide (BUD) plus as-needed terbutaline for preventing severe exacerbations but inferior for symptom control...Of participants randomised to as-needed BUD/FORM, 92% were confident/very confident in using it as a reliever. Conclusions Overall patients preferred as-needed BUD/FORM in mild asthma, especially those who had used this for 12 months in the PRACTICAL study
- |||||||||| budesonide / Generic Mfg.
12-year adherence to inhaled corticosteroids in adult-onset asthma (TP-14) - Aug 26, 2019 - Abstract #ERS2019ERS_4412;
Results Mean 12-year adherence to ICS was 69% (mean dispensed 2.5 (SD 1.8) g and mean prescribed 3.6 (SD 1.5) g budesonide equivalent per patient for 12 years)...Conclusions In patients with adult-onset asthma, adherence to ICS was relatively high. Better adherence to ICS was associated with features of more severe asthma, but adherence was not associated to symptoms or markers of inflammatory endotypes.
- |||||||||| budesonide / Generic Mfg.
Fractionated exhaled nitric oxide in COPD patients (6D) - Aug 26, 2019 - Abstract #ERS2019ERS_4092;
Methods Data of 450 patients included in the PREVENT study receiving standardized low-dose therapy with LABA/ICS (Budesonide 400ug/Formoterol 12 ug daily) with scheduled visits half-yearly at stable state and unscheduled visits for exacerbations and upper respiratory tract infections (URTI) were analyzed...Conclusion In a large COPD cohort on standardized low-dose ICS/LABA, COPD exacerbations, particularly the ones caused by a viral infection, are associated with increased FeNO levels. FeNO decreases to stable state values after convalescence.
- |||||||||| budesonide / Generic Mfg.
Exacerbation risk after night-time waking due to asthma in SYGMA 1 (RETIRO) - Aug 26, 2019 - Abstract #ERS2019ERS_3915;
P3
Introduction: In mild asthma, as-needed budesonide/formoterol (BUD/FORM) reduces exacerbation risk vs as-needed terbutaline, with similar reduction to BUD maintenance + as-needed terbutaline (SYGMA 1; NCT02149199)... In mild asthma, as-needed BUD/FORM reduces short-term exacerbation risk after two consecutive nights of asthma waking vs as-needed terbutaline, with comparable efficacy to BUD maintenance.
- |||||||||| budesonide / Generic Mfg.
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies (6D) - Aug 26, 2019 - Abstract #ERS2019ERS_3559;
P3
The hazard ratios for the time to first confirmed pneumonia for the budesonide 320 µg and budesonide 160 µg groups vs the non-ICS group were 0.80 (95% CI 0.50, 1.26) and 0.88 (95% CI 0.51, 1.51), respectively (Table). Conclusion : In patients with moderate-to-very severe COPD, pneumonia incidence with budesonide-containing therapies was low and was not increased vs non-ICS containing therapies.
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Omalizumab in severe asthma: real life study (TP-14) - Aug 26, 2019 - Abstract #ERS2019ERS_2666;
The following criteria were analyzed: number of exacerbations, forced expiratory volume in one second, symptoms (Asthma Control Test) and inhaled treatment in baseline and in 1 year after treatment initiation (equivalent daily dose of budesonide). After 12 months of Omalizumab, patients had symptomatic improvement (reduction of total exacerbations and higher scores in ACT), improvement in lung function (FEV1), reductions of daily mean dose of inhaled corticosteroids and suspension of oral corticosteroids, proving its therapeutic efficacy.
- |||||||||| budesonide / Generic Mfg.
Clinical Assessment of Glycopyrronium in COPD phenotypes and ACOS: Prospective, case control, observational study (TP-12) - Aug 26, 2019 - Abstract #ERS2019ERS_2625;
Results : Interim analyses for COPD (n=64) and ACO (n=64) on Glycopyrronium 50 mcg OD & Formoterol/Budesonide DPI inhalation with follow-up at 12 wks were analyzed...TEAEs included Pruritus (0.8 %), Pyrexia (0.8 %) of mild to moderate intensity. Conclusion : Glycopyrronium 50 mcg offers Therapeutic synergy for incremental bronchodilation that is meaningfully clinically significant (MCID) in Severe COPD or ACO
- |||||||||| budesonide / Generic Mfg.
Journal: Eosinophilic esophagitis: Pathophysiology, diagnosis, and management. (Pubmed Central) - Aug 22, 2019
...Swallowed topical steroids (budesonide in viscous gel or fluticasone propionate for nebulization) are an alternative, for which efficacy varies according to clinical and/or histological criteria and with relapses occurring at dosage tapering...The long-term risk of EoE is esophageal stenosis (25%) and endoscopic dilation may be repeated. Biotherapies have shown isolated histological improvement without significant clinical efficacy.
- |||||||||| budesonide / Generic mfg.
Journal: Is there a relationship between asthma and diabetes? (Pubmed Central) - Aug 22, 2019
The effect of asthma on diabetes does not seem to be significant, except for in patients with severe asthma. Inhaled steroids administered in low or mild doses do not affect fasting glycemia.
- |||||||||| Entyvio (vedolizumab) / Takeda
Clinical, Journal: Vedolizumab in refractory microscopic colitis: an international case series. (Pubmed Central) - Aug 21, 2019
In a series of highly refractory MC patients, vedolizumab induced clinical remission in 5/11 subjects, of whom 75% showed normalized histology. Larger randomized trials are needed to assess the efficacy of vedolizumab in patients with MC.
- |||||||||| budesonide / Generic Mfg.
Journal: Effect of terbutaline combined with budesonide in treatment of bronchial asthma and rehabilitation nursing. (Pubmed Central) - Aug 21, 2019
The results show that the interval medication of terbutaline and budesonide in the treatment of bronchial asthma can achieve better clinical efficacy and can provide reference for clinical treatment. In addition, this method can effectively reduce the level of inflammatory factors in acute asthma patients, thereby reducing the damage of inflammatory factors to the body.
|
